Wegovy Cost 2026:
Every Pricing Pathway

Wegovy's retail list price without insurance or any manufacturer program is $1,349 per month across all formats — the oral pill, the standard injector pen, and the HD pen. However, most cash-pay patients in 2026 do not pay this list price directly: Novo Nordisk's NovoCare Pharmacy cash-pay program offers the oral pill from approximately $149 to $299/month and the injectable pen from approximately $199/month (introductory, starter doses) to $349–$399/month (standard/HD doses). Compounded semaglutide through Luma Health (same active ingredient) is available at $197/month flat regardless of dose. Verify current NovoCare pricing directly at novocare.com, as these programs and their terms can change.

Yes. Novo Nordisk launched an oral formulation of Wegovy in January 2026, giving patients a needle-free option for weight management semaglutide for the first time. NovoCare Pharmacy cash pricing for the pill generally ranges from approximately $149 to $299 per month depending on dose, with introductory pricing on some doses subject to change later in 2026. Verify current pill pricing and dose availability directly at novocare.com.

For eligible patients, Novo Nordisk's manufacturer savings offer can reduce a Wegovy fill to as little as $25, with a maximum monthly savings benefit of $100 and an annual cap of $4,600, applied per 28-day fill. This requires active commercial insurance that covers Wegovy and, in most cases, prior authorization. The savings offer does not apply to Medicare Part D beneficiaries (who instead may access the new Medicare GLP-1 Bridge), Medicaid patients, or patients without commercial insurance. Patients who cannot access the savings offer should evaluate NovoCare Pharmacy cash pricing ($149–$399/month depending on format and dose) or compounded semaglutide ($197/month flat) as alternatives.

The Medicare GLP-1 Bridge is a new program scheduled to launch July 1, 2026, intended to give eligible Medicare Part D beneficiaries access to Wegovy for approximately $50/month — a significant change, since traditional Medicare Part D has historically not covered GLP-1 medications prescribed primarily for weight management. As a newly announced program at the time of this writing, specific eligibility criteria and which Part D plans participate should be confirmed directly through Medicare.gov or your plan administrator closer to and after the launch date.

Compounded semaglutide contains the same active pharmaceutical molecule as Wegovy — semaglutide — at the same therapeutic doses. The pharmacological mechanism (GLP-1 receptor activation) and expected clinical outcomes are attributed to the active molecule. Differences: Wegovy is an FDA-approved finished drug product from Novo Nordisk, available as an oral pill or auto-injector pen with full regulatory assurance of an FDA drug approval. Compounded semaglutide is prepared per individual prescription by a licensed 503A sterile compounding pharmacy, delivered in a multi-dose vial, and is not itself FDA-approved as a finished drug product — meaning it is not proven bioequivalent through the same clinical trial and manufacturing oversight process.

Wegovy and Ozempic both contain semaglutide but are approved for different indications and doses. Wegovy is FDA-approved for chronic weight management at up to 2.4 mg/week (or 7.2 mg HD pen). Ozempic is FDA-approved for type 2 diabetes at up to 2.0 mg/week. At retail, Ozempic is typically somewhat less expensive than Wegovy. Both have separate manufacturer savings programs; patients seeking semaglutide for weight loss are generally better served pursuing Wegovy (the weight-management-indicated product) or compounded semaglutide, both of which support dosing up to 2.4 mg/week.